References

  1. Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open. 2020;3(6):e207954.
  2. Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000-2020. PLoS One. 2018;13(11):e0207005.
  3. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2018. HIV Surveillance Report (Updated). 2020:31.
  4. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158(5):1079-1083.
  5. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-1799.
  6. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245-2252.
  7. Becker JT, Kingsley LA, Molsberry S, et al. Cohort profile: recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study. Int J Epidemiol. 2015;44(5):1506-1516.
  8. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243-1250.
  9. Pumpradit W, Ananworanich J, Lolak S, et al. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol. 2010;16(1):76-82.
  10. Haddow LJ, Laverick R, Daskalopoulou M, et al. Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav. 2018;22(5):1573-1583.
  11. Lawler K, Mosepele M, Ratcliffe S, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc. 2010;13:15.
  12. Aung HL, Aghvinian M, Gouse H, et al. Is there any evidence of premature, accentuated and accelerated aging effects on neurocognition in people living with HIV? A systematic review. AIDS Behav. 2021;25(3):917-960.
  13. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357(9251):169-175.
  14. Soontornniyomkij V, Umlauf A, Chung SA, et al. HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS. 2014;28(9):1297-1306.
  15. Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013;10(3):199-206.
  16. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60(4):351-358.
  17. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS. 2011;25(13):1637-1646.
  18. Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database. J Am Heart Assoc. 2019;8(14):e012241.
  19. D’Ascenzo F, Cerrato E, Calcagno A, et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015;240(1):197-204.
  20. McKibben RA, Margolick JB, Grinspoon S, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis. 2015;211(8):1219-1228.
  21. Castilho JL, Shepherd BE, Koethe J, et al. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS. 2016;30(6):899-908.
  22. Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93-100.
  23. Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol. 2015;24(5):279-282.
  24. Imamichi H, Smith M, Adelsberger JW, et al. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci U S A. 2020;117(7):3704-3710.
  25. DeMaster LK, Liu X, VanBelzen DJ, et al. A subset of CD4/CD8 double-negative T cells expresses HIV proteins in patients on antiretroviral therapy. J Virol. 2015;90(5):2165-2179.
  26. Williams B, Landay A, Presti RM. Microbiome alterations in HIV infection a review. Cell Microbiol. 2016;18(5):645-651.
  27. Chan P, Spudich S. Investigating vascular diseases in people living with HIV by nuclear imaging. J Nucl Cardiol. 2021.
  28. Noubissi EC, Katte JC, Sobngwi E. Diabetes and HIV. Curr Diab Rep. 2018;18(11):125.
  29. Mirza FS, Luthra P, Chirch L. Endocrinological aspects of HIV infection. J Endocrinol Invest. 2018;41(8):881-899.
  30. Beydoun MA, Dore GA, Canas JA, et al. Systemic inflammation is associated with longitudinal changes in cognitive performance among urban adults. Front Aging Neurosci. 2018;10:313.
  31. Walker KA, Gottesman RF, Wu A, et al. Systemic inflammation during midlife and cognitive change over 20 years: the ARIC Study. Neurology. 2019;92(11):e1256-e1267.
  32. Ulfhammer G, Edén A, Mellgren Å, et al. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. AIDS. 2018;32(15):2171-2178.
  33. Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196(12):1779-1783.
  34. Cysique LA, Jugé L, Gates T, et al. Covertly active and progressing neurochemical abnormalities in suppressed HIV infection. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e430.
  35. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5):625-633.
  36. Rubin LH, Sacktor N, Creighton J, et al. Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy. AIDS. 2018;32(12):1661-1667.
  37. Vera JH, Guo Q, Cole JH, et al. Neuroinflammation in treated HIV-positive individuals: A TSPO PET study. Neurology. 2016;86(15):1425-1432.
  38. Garvey LJ, Pavese N, Politis M, et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS. 2014;28(1):67-72.
  39. Clifford DB, Fagan AM, Holtzman DM, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 2009;73(23):1982-1987.
  40. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005;65(9):1490-1492.
  41. Mohamed M, Skolasky RL, Zhou Y, et al. Beta-amyloid (A-beta) uptake by PET imaging in older HIV+ and HIV- individuals. J Neurovirol. 2020;26(3):382-390.
  42. Howdle GC, Quidé Y, Kassem MS, et al. Brain amyloid in virally suppressed HIV-associated neurocognitive disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e739.
  43. Hellmuth J, Milanini B, Masliah E, et al. A neuropathologic diagnosis of Alzheimer’s disease in an older adult with HIV-associated neurocognitive disorder. Neurocase. 2018;24(4):213-219.
  44. Turner RS, Chadwick M, Horton WA, Simon GL, Jiang X, Esposito G. An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition. Alzheimers Dement (Amst). 2016;4:1-5.
  45. Makitalo S, Mellgren A, Borgh E, et al. The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease. AIDS Res Ther. 2015;12:23.
  46. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275-282.
  47. Kore I, Ananworanich J, Valcour V, et al. Neuropsychological impairment in acute HIV and the effect of immediate antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70(4):393-399.
  48. Hellmuth J, Colby D, Valcour V, et al. Depression and anxiety are common in acute HIV infection and associate with plasma immune activation. AIDS Behav. 2017;21(11):3238-3246.
  49. Rubin LH, Maki PM, Springer G, et al. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression. Neurology. 2017;89(15):1594-1603.
  50. Cole JH, Caan MWA, Underwood J, et al. No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus: longitudinal neuroimaging results from the comorbidity in relation to AIDS (COBRA) project. Clin Infect Dis. 2018;66(12):1899-1909.
  51. De Francesco D, Underwood J, Post FA, et al. Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis. 2016;16(1):617.
  52. Grant I, Franklin DR, Jr., Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055-2062.
  53. Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016;86(4):334-340.
  54. Brouillette MJ, Yuen T, Fellows LK, Cysique LA, Heaton RK, Mayo NE. Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER Cohort using group-based trajectory analysis. PLoS One. 2016;11(5):e0155766.
  55. Gott C, Gates T, Dermody N, Brew BJ, Cysique LA. Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity. PLoS One. 2017;12(3):e0171887.
  56. Masters MC, Perez J, Wu K, et al. Baseline neurocognitive impairment (NCI) is associated with incident frailty but baseline frailty does not predict incident NCI in older persons with HIV. Clin Infect Dis. 2021;73(4):680-688.
  57. Stuss DT, Murphy KJ, Binns MA, Alexander MP. Staying on the job: the frontal lobes control individual performance variability. Brain. 2003;126(Pt 11):2363-2380.
  58. MacDonald SW, Hultsch DF, Dixon RA. Performance variability is related to change in cognition: evidence from the Victoria Longitudinal Study. Psychol Aging. 2003;18(3):510-523.
  59. Duchek JM, Balota DA, Tse CS, Holtzman DM, Fagan AM, Goate AM. The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer’s disease. Neuropsychology. 2009;23(6):746-758.
  60. Gleason CE, Norton D, Anderson ED, et al. Cognitive variability predicts incident Alzheimer’s disease and mild cognitive impairment comparable to a cerebrospinal fluid biomarker. J Alzheimers Dis. 2018;61(1):79-89.
  61. Costa AS, Dogan I, Schulz JB, Reetz K. Going beyond the mean: intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders. Clin Neuropsychol. 2019;33(2):369-389.
  62. Kalin AM, Pflüger M, Gietl AF, et al. Intraindividual variability across cognitive tasks as a potential marker for prodromal Alzheimer’s disease. Front Aging Neurosci. 2014;6:147.
  63. Halliday DWR, Gawryluk JR, Garcia-Barrera MA, MacDonald SWS. White matter integrity is associated with intraindividual variability in neuropsychological test performance in healthy older adults. Front Hum Neurosci. 2019;13:352.
  64. Jackson JD, Balota DA, Duchek JM, Head D. White matter integrity and reaction time intraindividual variability in healthy aging and early-stage Alzheimer disease. Neuropsychologia. 2012;50(3):357-366.
  65. Hultsch DF, MacDonald SW, Dixon RA. Variability in reaction time performance of younger and older adults. J Gerontol B Psychol Sci Soc Sci. 2002;57(2):P101-P115.
  66. Rabbitt P, Osman P, Moore B, Stollery B. There are stable individual differences in performance variability, both from moment to moment and from day to day. Q J Exp Psychol A. 2001;54(4):981-1003.
  67. West R, Murphy KJ, Armilio ML, Craik FI, Stuss DT. Lapses of intention and performance variability reveal age-related increases in fluctuations of executive control. Brain Cogn. 2002;49(3):402-419.
  68. Du Plessis S, Vink M, Joska JA, Koutsilieri E, Stein DJ, Emsley R. HIV infection and the fronto-striatal system: a systematic review and meta-analysis of fMRI studies. AIDS. 2014;28(6):803-811.
  69. Morgan EE, Woods SP, Delano-Wood L, Bondi MW, Grant I, HNRP Group. Intraindividual variability in HIV infection: evidence for greater neurocognitive dispersion in older HIV seropositive adults. Neuropsychology. 2011;25(5):645-654.
  70. Bauer LO. HIV/AIDS and an overweight body mass are associated with excessive intra-individual variability in response preparation. J Neurovirol. 2018;24(5):577-586.
  71. Levine AJ, Martin E, Munro CA, et al. Intraindividual variability in neurocognitive performance: No influence due to HIV status or self-reported effort. J Clin Exp Neuropsychol. 2018;40(10):1044-1049.
  72. Thaler NS, Sayegh P, Arentoft A, Thames AD, Castellon SA, Hinkin CH. Increased neurocognitive intra-individual variability is associated with declines in medication adherence in HIV-infected adults. Neuropsychology. 2015;29(6):919-925.
  73. Morgan EE, Woods SP, Grant I, HNRP Group. Intra-individual neurocognitive variability confers risk of dependence in activities of daily living among HIV-seropositive individuals without HIV-associated neurocognitive disorders. Arch Clin Neuropsychol. 2012;27(3):293-303.
  74. Anderson AE, Jones JD, Thaler NS, Kuhn TP, Singer EJ, Hinkin CH. Intraindividual variability in neuropsychological performance predicts cognitive decline and death in HIV. Neuropsychology. 2018;32(8):966-972.
  75. Hines LJ, Miller EN, Hinkin CH, et al. Cortical brain atrophy and intra-individual variability in neuropsychological test performance in HIV disease. Brain Imaging Behav. 2016;10(3):640-651.
  76. Jones JD, Kuhn T, Mahmood Z, Singer EJ, Hinkin CH, Thames AD. Longitudinal intra-individual variability in neuropsychological performance relates to white matter changes in HIV. Neuropsychology. 2018;32(2):206-212.
  77. British HIV Association, Angus B, Brook G, et al. BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update).
  78. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations – 2016 update. Geneva, Switzerland:Guidelines Review Committee, HIV/AIDS;2016.
  79. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651-1669.
  80. Metral M, Nadin I, Locatelli I, et al. How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? HIV Med. 2020;21(5):342-348.
  81. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(3):273-278.
  82. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19(13):1367-1374.
  83. Janssen MA, Bosch M, Koopmans PP, Kessels RP. Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients. J Neurovirol. 2015;21(4):383-390.
  84. López E, Steiner AJ, Smith K, et al. Diagnostic utility of the HIV Dementia Scale and the International HIV Dementia Scale in screening for HIV-associated neurocognitive disorders among Spanish-speaking adults. Appl Neuropsychol Adult. 2017;24(6):512-521.
  85. Sakamoto M, Marcotte TD, Umlauf A, et al. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013;62(1):36-42.
  86. Nakku J, Kinyanda E, Hoskins S. Prevalence and factors associated with probable HIV dementia in an African population: a cross-sectional study of an HIV/AIDS clinic population. BMC Psychiatry. 2013;13:126.
  87. Joska JA, Westgarth-Taylor J, Myer L, et al. Characterization of HIV-associated neurocognitive disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav. 2011;15(6):1197-1203.
  88. Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology. 2007;68(5):350-355.
  89. van den Dries LWJ, Wagener MN, Jiskoot LC, et al. Neurocognitive impairment in a chronically well-suppressed HIV-infected population: the Dutch TREVI Cohort Study. AIDS Patient Care STDS. 2017;31(8):329-334.
  90. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
  91. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
  92. Ganasen KA, Fincham D, Smit J, Seedat S, Stein D. Utility of the HIV Dementia Scale (HDS) in identifying HIV dementia in a South African sample. J Neurol Sci. 2008;269(1-2):62-64.
  93. Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10(4):246-252.
  94. Milanini B, Wendelken LA, Esmaeili-Firidouni P, Chartier M, Crouch PC, Valcour V. The Montreal cognitive assessment to screen for cognitive impairment in HIV patients older than 60 years. J Acquir Immune Defic Syndr. 2014;67(1):67-70.
  95. Robbins RN, Gouse H, Brown HG, et al. A mobile app to screen for neurocognitive impairment: preliminary validation of NeuroScreen among HIV-infected South African adults. JMIR Mhealth Uhealth. 2018;6(1):e5.
  96. Robbins RN, Brown H, Ehlers A, et al. A smartphone app to screen for HIV-related neurocognitive impairment. J Mob Technol Med. 2014;3(1):23-26.
  97. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165-178.
  98. Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21(2):185-194.
  99. Bloch M, Kamminga J, Jayewardene A, et al. A screening strategy for HIV-associated neurocognitive disorders that accurately identifies patients requiring neurological review. Clin Infect Dis. 2016;63(5):687-693.
  100. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70.
  101. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45-55.
  102. Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17(7):1233-1242.
  103. Woollard SM, Kanmogne GD. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015;9:5447-5468.
  104. Winston A, Antinori A, Cinque P, et al. Defining cerebrospinal fluid HIV RNA escape: editorial review AIDS. AIDS. 2019;33 Suppl 2:S107-S111.